Bristol-Myers Squibb Settles FCPA Case for $14 Million
Pharmaceutical giant Bristol-Myers Squibb has reached a $14 million settlement with the SEC for violations of the Foreign Corrupt Practices Act. According to the Commission, the company’s joint venture in China made cash payments and provided other benefits to healthcare providers at state-owned and state-controlled hospitals in exchange for prescription ...
Related articles
-
Blog
Justice Department Ends Bristol-Myers Squibb FCPA Probe
The Department of Justice has ended its investigation into allegations that pharmaceutical giant Bristol-Myers Squibb violated the Foreign Corrupt Practices Act. Earlier this month the company reached a $14 million settlement with the SEC for FCPA violations relating to certain sales and marketing practices in China. More inside.
-
ArticleDOJ dismisses indictment against Cassava advisor amid legal flaws
The DOJ dropped a June 2024 indictment against a Cassava Sciences advisor, closing a case tied to an alleged short-selling scheme and related government probes. The case was criticized for fundamental flaws in evidence and legal procedures.
-
News BriefTexas gas company found that its merger acquisition paid a cartel-connected entity
A Texas-based gas company has disclosed that a Mexican affiliate made payments to local government officials that may have benefited a cartel designated as a terrorist group by the U.S. government. Entanglement with cartels is an increasing risk for companies doing business in Mexico.